Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
INO Stock Overview
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Inovio Pharmaceuticals Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.94 |
52 Week High | US$9.96 |
52 Week Low | US$1.38 |
Beta | 0.82 |
1 Month Change | -2.51% |
3 Month Change | -45.66% |
1 Year Change | -78.98% |
3 Year Change | -34.01% |
5 Year Change | -75.26% |
Change since IPO | -96.71% |
Recent News & Updates
Shareholder Returns
INO | US Biotechs | US Market | |
---|---|---|---|
7D | 21.3% | 10.3% | 6.6% |
1Y | -79.0% | -24.3% | -18.4% |
Return vs Industry: INO underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: INO underperformed the US Market which returned -18.4% over the past year.
Price Volatility
INO volatility | |
---|---|
INO Average Weekly Movement | 14.7% |
Biotechs Industry Average Movement | 13.2% |
Market Average Movement | 8.1% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: INO is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.
Volatility Over Time: INO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1979 | 317 | Jacqueline Shea | https://www.inovio.com |
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever.
Inovio Pharmaceuticals Fundamentals Summary
INO fundamental statistics | |
---|---|
Market Cap | US$444.34m |
Earnings (TTM) | -US$328.33m |
Revenue (TTM) | US$1.60m |
277.5x
P/S Ratio-1.4x
P/E RatioIs INO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
INO income statement (TTM) | |
---|---|
Revenue | US$1.60m |
Cost of Revenue | US$266.17m |
Gross Profit | -US$264.57m |
Other Expenses | US$63.76m |
Earnings | -US$328.33m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -1.43 |
Gross Margin | -16,507.76% |
Net Profit Margin | -20,485.92% |
Debt/Equity Ratio | 4.6% |
How did INO perform over the long term?
See historical performance and comparisonValuation
Is INO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INO?
Other financial metrics that can be useful for relative valuation.
What is INO's n/a Ratio? | |
---|---|
n/a Ratio | 0x |
n/a | n/a |
Market Cap | US$444.34m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 73.4x |
Enterprise Value/EBITDA | -0.4x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does INO's PB Ratio compare to its peers?
INO PB Ratio vs Peers |
---|
Company | PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2.3x | ||
VXRT Vaxart | 2.9x | 76.0% | US$478.0m |
BLUE bluebird bio | 1.2x | 26.5% | US$314.4m |
LXRX Lexicon Pharmaceuticals | 3.3x | 42.0% | US$303.7m |
VBIV VBI Vaccines | 1.8x | 70.2% | US$236.8m |
INO Inovio Pharmaceuticals | 1.3x | 40.9% | US$444.3m |
Price-To-Book vs Peers: INO is good value based on its Price-To-Book Ratio (1.3x) compared to the peer average (2.3x).
Price to Earnings Ratio vs Industry
How does INO's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: INO is good value based on its Price-To-Book Ratio (1.3x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is INO's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 1.3x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate INO's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of INO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate INO's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate INO's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate INO's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Inovio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Future Growth Score
2/6Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
40.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INO is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: INO is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: INO is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: INO's revenue (75% per year) is forecast to grow faster than the US market (8.4% per year).
High Growth Revenue: INO's revenue (75% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INO's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Past Performance
How has Inovio Pharmaceuticals performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-27.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: INO is currently unprofitable.
Growing Profit Margin: INO is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: INO is unprofitable, and losses have increased over the past 5 years at a rate of 27% per year.
Accelerating Growth: Unable to compare INO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: INO has a negative Return on Equity (-92.47%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Inovio Pharmaceuticals's financial position?
Financial Health Score
5/6Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: INO's short term assets ($399.9M) exceed its short term liabilities ($59.4M).
Long Term Liabilities: INO's short term assets ($399.9M) exceed its long term liabilities ($31.1M).
Debt to Equity History and Analysis
Debt Level: INO has more cash than its total debt.
Reducing Debt: Insufficient data to determine if INO's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: INO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: INO has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 29.8% each year.
Discover healthy companies
Dividend
What is Inovio Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate INO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate INO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if INO's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INO's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as INO has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
1.7yrs
Average management tenure
CEO
Jacqueline Shea (55 yo)
0.083
Tenure
US$2,310,157
Compensation
Dr. Jacqueline E. Shea, Ph D., serves as its Chief Executive Officer & President at Inovio Pharmaceuticals, Inc. since May 10, 2022 and serves as its Director since May 16, 2022. Dr. Shea served as Chief O...
CEO Compensation Analysis
Compensation vs Market: Jacqueline's total compensation ($USD2.31M) is about average for companies of similar size in the US market ($USD2.83M).
Compensation vs Earnings: Jacqueline's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: INO's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
Experienced Board: INO's board of directors are considered experienced (3.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.4%.
Top Shareholders
Company Information
Inovio Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
Key Information
- Name: Inovio Pharmaceuticals, Inc.
- Ticker: INO
- Exchange: NasdaqGS
- Founded: 1979
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$444.340m
- Shares outstanding: 229.04m
- Website: https://www.inovio.com
Number of Employees
Location
- Inovio Pharmaceuticals, Inc.
- 660 West Germantown Pike
- Suite 110
- Plymouth Meeting
- Pennsylvania
- 19462
- United States
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/06/26 00:00 |
End of Day Share Price | 2022/06/24 00:00 |
Earnings | 2022/03/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.